NEW YORK (GenomeWeb News) – Asterand said today that it has extended its drug-discovery and development collaboration with Bristol-Myers Squibb for up to three years.

Under the agreement, BMS will continue to have access to Asterand's PhaseZERO drug-discovery services and XpressBANK human tissue and clinical sample bank for early drug-target validation and compound optimization.

BMS may also use Asterand's ProCURE custom clinical sample collection service, Asterand said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.